Biotech reverse mergers are becoming more acceptable and are more commonplace this year. But startups are already ramping up for IPOs during the first half of…

TenNor Therapeutics has secured a $25 million Series B round to get it into Phase III testing for its lead GI antibiotic candidate.

Abingworth is seeding a solid tumor-focused British immuno-oncology startup based on the work of gamma-delta T cell pioneer Adrian Hayday.

Perennial life science investors Atlas and Sofinnova have co-led a $35 million startup funding round for Delinia, a newly emerged biotech that starts life with…

Alzheimer’s specialist AC Immune, which lists Biogen, Genentech and Johnson & Johnson among its partners, has set the terms for its long-mooted Nasdaq IPO.

Third Rock Ventures’ Relay Therapeutics has broken from its 12-month stealth mode with a $57 million Series A cash boost as it looks to create a next-…

A startup based on the work of gene therapy pioneer Nathalie Cartier-Lacave has secured Series A funds to advance programs against Huntington's and…

Prostate cancer biotech Advantagene has raised a little over $14 million for its experimental immune-oncology med, although it has had to use an “alternative”…

The VC wing of Novartis has joined with Fountain Healthcare Partners to lead a $17 million round in Inflazome, a chronic inflammatory disease startup.